Joseph Schérer

683 total citations
27 papers, 468 citations indexed

About

Joseph Schérer is a scholar working on Hepatology, Infectious Diseases and Virology. According to data from OpenAlex, Joseph Schérer has authored 27 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 14 papers in Infectious Diseases and 7 papers in Virology. Recurrent topics in Joseph Schérer's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (13 papers) and HIV Research and Treatment (7 papers). Joseph Schérer is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (13 papers) and HIV Research and Treatment (7 papers). Joseph Schérer collaborates with scholars based in Germany, United States and Canada. Joseph Schérer's co-authors include David B. Hall, John D. Baxter, Jonathan Schapiro, Charles A. Boucher, Veronika Kohlbrenner, George Kukolj, Douglas L. Mayers, Jerry O. Stern, Klaus Tatsch and Gerhard Steinmann and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Joseph Schérer

26 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph Schérer Germany	10	227	213	190	141	40	27	468
J. Marquie-Beck United States	6	41 0.2×	206 1.0×	93 0.5×	294 2.1×	21 0.5×	6	407
Baiba Rozentāle Latvia	10	39 0.2×	154 0.7×	83 0.4×	45 0.3×	21 0.5×	24	398
Małgorzata Zalewska Poland	10	127 0.6×	54 0.3×	150 0.8×	23 0.2×	23 0.6×	42	294
Linda M. Page United States	11	29 0.1×	355 1.7×	63 0.3×	288 2.0×	15 0.4×	13	594
George Beatty United States	12	51 0.2×	323 1.5×	82 0.4×	242 1.7×	9 0.2×	18	479
Pierre Cappy France	7	49 0.2×	71 0.3×	150 0.8×	19 0.1×	12 0.3×	23	234
Ali Sepehrinezhad Iran	9	73 0.3×	55 0.3×	95 0.5×	43 0.3×	6 0.1×	20	280
Haryes A. Funes Spain	8	26 0.1×	240 1.1×	92 0.5×	243 1.7×	15 0.4×	9	427
Ivan Schietroma Italy	12	36 0.2×	96 0.5×	73 0.4×	138 1.0×	6 0.1×	12	347
M. Raptopoulou Greece	11	219 1.0×	41 0.2×	246 1.3×	9 0.1×	23 0.6×	22	327

Countries citing papers authored by Joseph Schérer

Since Specialization

Citations

This map shows the geographic impact of Joseph Schérer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Schérer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Schérer more than expected).

Fields of papers citing papers by Joseph Schérer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Schérer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Schérer. The network helps show where Joseph Schérer may publish in the future.

Co-authorship network of co-authors of Joseph Schérer

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Schérer. A scholar is included among the top collaborators of Joseph Schérer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Schérer. Joseph Schérer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xylaki, Mary, Joseph Schérer, Mohammed Dakna, et al.. (2025). Proteomic Exploration of L1CAM+-Extracellular Vesicles from Plasma of Manifest and Prodromal Parkinson’s Disease. International Journal of Molecular Sciences. 26(23). 11564–11564.

Cooper, David A., Damien V. Cordery, Roberto Zajdenverg, et al.. (2016). Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. PLoS ONE. 11(1). e0144917–e0144917. 4 indexed citations

Berger, Kristi L., Christoph Sarrazin, David R. Nelson, et al.. (2016). Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. PLoS ONE. 11(8). e0160668–e0160668. 5 indexed citations

Berger, Kristi L., et al.. (2015). Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. Antimicrobial Agents and Chemotherapy. 59(10). 6017–6025. 8 indexed citations

Berger, Kristi L., C. Sarrazin, Péter Ferenci, et al.. (2014). P1226 NS3 Q80K DID NOT IMPACT EFFICACY OR TREATMENT-EMERGENT RESISTANCE PATTERNS IN HCV GENOTYPE 1-INFECTED PATIENTS RECEIVING FALDAPREVIR + PEGINTERFERON/RIBAVIRIN IN THREE PHASE III TRIALS. Journal of Hepatology. 60(1). S497–S497. 1 indexed citations

Jensen, Donald M., Graham R. Foster, Peter Ferenci, et al.. (2014). Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2). Gastroenterology. 146(5). S–974. 5 indexed citations

Sulkowski, Mark S., Marc Bourlière, Jean-Pierre Bronowicki, et al.. (2013). Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology. 57(6). 2155–2163. 60 indexed citations

Sulkowski, Mark, Tarik Asselah, Jacob Lalezari, et al.. (2013). Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology. 57(6). 2143–2154. 86 indexed citations

Berger, Kristi L., Ibtissem Triki, Mireille Cartier, et al.. (2013). Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir. Antimicrobial Agents and Chemotherapy. 58(2). 698–705. 29 indexed citations

10.

Kukolj, George, Richard C. Bethell, Mariano Cartier, et al.. (2012). 1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS. Journal of Hepatology. 56. S469–S469. 4 indexed citations

11.

Aslanyan, Stella, et al.. (2011). Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers. Current HIV Research. 9(4). 237–246. 5 indexed citations

12.

Bethell, Richard C., Joseph Schérer, Myriam Witvrouw, et al.. (2011). Short Communication: Phenotypic Protease Inhibitor Resistance and Cross-Resistance in the Clinic from 2006 to 2008 and Mutational Prevalences in HIV from Patients with Discordant Tipranavir and Darunavir Susceptibility Phenotypes. AIDS Research and Human Retroviruses. 28(9). 1019–1024. 7 indexed citations

13.

Pol, S., Thomas Berg, Maurizio Bonacini, et al.. (2011). 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV. Journal of Hepatology. 54. S486–S486. 1 indexed citations

14.

Schapiro, Jonathan, Joseph Schérer, Charles A. Boucher, et al.. (2010). Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score. Antiviral Therapy. 15(7). 1011–1019. 16 indexed citations

15.

Walmsley, Sharon, Kathleen Squires, Laurence Weiss, et al.. (2009). Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS. 23(3). 429–431. 9 indexed citations

16.

Baxter, John D., Jonathan Schapiro, Charles A. Boucher, et al.. (2006). Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir. Journal of Virology. 80(21). 10794–10801. 108 indexed citations

17.

Sobizack, N., et al.. (1999). Neuropsychologische Defizite bei ersterkrankten schizophrenen Patienten. Der Nervenarzt. 70(5). 408–415. 4 indexed citations

18.

Schérer, Joseph, Klaus Tatsch, Johannes Schwarz, et al.. (1994). Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biological Psychiatry. 36(9). 627–629. 23 indexed citations

19.

Oertel, W. H., Klaus Tatsch, Johannes Schwarz, et al.. (1992). Decrease of D2 receptors indicated by ¹²³I‐iodobenzamide single‐photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Annals of Neurology. 32(6). 743–748. 38 indexed citations

20.

Schérer, Joseph. (1970). Die Wirtschaftsverfassung der EWG. Nomos eBooks. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact